Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, week 18 and 22
Awards & highlights
Summary
This double-blind placebo-controlled study will assess the tolerability, feasibility, and pharmacodynamics of intradermal Hair Stimulating Complex (HSC) in up to 18 of 27 women with Ludwig 1 or 2 classification or the Savin Frontal classification of hair loss. Safety measures include vital signs, dermatological examination of the scalp, pre- and post-dose blood and urine collection, as well as Investigator Global Assessments and subject self assessments throughout the 22-week study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1, week 18 and 22
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, week 18 and 22
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Adverse Events due to HSC
Secondary outcome measures
Investigator Assessments of Global Photographs compared to baseline
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Hair Stimulating ComplexExperimental Treatment1 Intervention
Hair Stimulating Complex (HSC) is derivative of hypoxia-induced multipotent cell conditioned media enriched for certain key growth factors
Group II: Phosphate Buffered SalinePlacebo Group1 Intervention
Phosphate Buffered Saline
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
HistogenLead Sponsor
5 Previous Clinical Trials
369 Total Patients Enrolled
2 Trials studying Alopecia
92 Patients Enrolled for Alopecia
Share this study with friends
Copy Link
Messenger